NCT01086501View on ClinicalTrials.gov

ESOXC-ER Efficacy and Safety of an Extended Release (ER) Formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients

CompletedOBSERVATIONAL
Enrollment

225

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

October 31, 2012

Conditions
Epilepsy
Trial Locations (1)

80333

Dr. Stephan Arnold, Munich

Sponsors
All Listed Sponsors
lead

Desitin Arzneimittel GmbH

INDUSTRY